Chronic kidney disease is reaching epidemic proportions in the aging populations of industrialised countries, and this trend has motivated the development of more stringent guidelines for treatment goals in ESRD patients. It is now appropriate to continue the impetus towards patient management by considering new treatments and their implications. For all healthcare professionals working in the field of nephrology, the development of phosphate binding therapy has significantly improved the treatment and care of patients.

A history of phosphate control and aluminium treatments in end-stage renal disease (ESRD) and hyperphosphataemia. Aluminium accumulation in renal patients and aluminium-related bone disease (ARBD).